You are here: Welcome » Hydroxychloroquine

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
hydroxychloroquine [2022/06/07 06:52]
mathew 		hydroxychloroquine [2022/12/13 12:07] (current)
pamela [Pfizer Recomends Hydroxychloroquine for SARS-CoV-2 Treatment]
Line 34: Line 34:
  
 There was one single rationale paper for repurposing medicine published during the early going of the pandemic that did not include any discussion at all of hydroxychloroquine, despite its being the obvious first choice. That's the one that has NIAID Director Dr. Anthony Fauci's name on it. There was one single rationale paper for repurposing medicine published during the early going of the pandemic that did not include any discussion at all of hydroxychloroquine, despite its being the obvious first choice. That's the one that has NIAID Director Dr. Anthony Fauci's name on it.
 +
 +==== Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture ====
 +
 +Published: 14 September 2022  {{ ::hcq_blocks_sars_study.png?600|}}
 +
 +Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture
 +
 +Zixuan Yuan, Mahmud Arif Pavel, Hao Wang, Jerome C. Kwachukwu, Sonia Mediouni, Joseph Anthony Jablonski, Kendall W. Nettles, Chakravarthy B. Reddy, Susana T. Valente & Scott B. Hansen 
 +
 +Communications Biology volume 5, Article number: 958 (2022) Cite this article
 +
 +
 +Abstract
 +
 +[[:Hydroxychloroquine]] (HCQ), a drug used to treat lupus and malaria, was proposed as a treatment for SARS-coronavirus-2 (SARS-CoV-2) infection, albeit with controversy. In vitro, HCQ effectively inhibits viral entry, but its use in the clinic has been hampered by conflicting results. A better understanding of HCQ’s mechanism of actions in vitro is needed. 
 +
 +Recently, anesthetics were shown to disrupt ordered clusters of monosialotetrahexosylganglioside1 (GM1) lipid. These same lipid clusters recruit the [[:SARS-CoV-2]] surface receptor angiotensin converting enzyme 2 ([[:ACE2]]) to endocytic lipids, away from phosphatidylinositol 4,5 bisphosphate (PIP2) clusters. 
 +
 +Here we employed super-resolution imaging of cultured mammalian cells (VeroE6, A549, H1793, and HEK293T) to show HCQ directly perturbs clustering of ACE2 receptor with both endocytic lipids and PIP2 clusters. In elevated (high) cholesterol, HCQ moves ACE2 nanoscopic distances away from endocytic lipids. In cells with resting (low) cholesterol, ACE2 primarily associates with PIP2 clusters, and HCQ moves ACE2 away from PIP2 clusters—erythromycin has a similar effect. 
 +
 +We conclude** HCQ inhibits viral entry through two distinct mechanisms** in high and low tissue cholesterol and does so prior to inhibiting cathepsin-L. HCQ clinical trials and animal studies will need to account for tissue cholesterol levels when evaluating dosing and efficacy. ((https://web.archive.org/web/20220915001517/https://www.nature.com/articles/s42003-022-03841-8))
 +
 +==== Pfizer Recomends Hydroxychloroquine for SARS-CoV-2 Treatment ====
 +{{ ::pfizer_hcq_treats_covid_text_box_large.png?400|}}
 +[[:Pfizer]] STILL Recommends Hydroxychloroquine for the Treatment of Severe Covid Disease
 +How can we ever trust SCIENCE again after such a blatant heresy by its flesh-and-blood corporate theophany?
 +
 +Substack - December 13, 2022 by Ashmedai
 +
 +If you just want to see where Pfizer recommends HCQ and skip the article, it is on page 13 here.((https://web.archive.org/web/20221213102408/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/343db662-0565-4062-8956-00ddd5bb4fbb/COVID-19%20Antiviral%20-%202.%20Clinical%20Presentation-Proactive.pdf))
 +
 +I discovered a while back that Pfizer recommends [[:Hydroxychloroquine]] for the treatment of severe late-stage covid disease.
 +{{ ::pfizer_hcq_treats_covid_-_mechanism_page.png?400|}}
 +
 +On a whim, I decided to check to see if [[:Pfizer]] was still recommending HCQ. I suspected that there was a pretty good chance that Pfizer had pulled their prior guidance, because not only should it be a profound embarrassment to be caught advocating for the most salacious and vile lunatic disinformation of the pandemic (besides the anti-covid vaccine claims), Pfizer also now had an added incentive to push people towards [[:Paxlovid]].
 +
 +Initially, it seemed like Pfizer had pulled their little slide deck with the heretical medical advice DISINFORMATION, because when I tried the link I put in the original article above - COVID 19: Clinical Presentation - it led to this - 404 Page Not Found ((https://ashmedai.substack.com/p/pfizer-still-recommends-hydroxychloroquine))((https://web.archive.org/web/20221213103130/https://ashmedai.substack.com/p/pfizer-still-recommends-hydroxychloroquine))
 +
 +
 +NOTE - Pfizer pdf references at Wayback copies w first link to HCQ diagram above ((https://web.archive.org/web/20221213102408/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/343db662-0565-4062-8956-00ddd5bb4fbb/COVID-19%20Antiviral%20-%202.%20Clinical%20Presentation-Proactive.pdf))((https://web.archive.org/web/20220617175326/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/a2d18154-9f98-4b5a-b451-8dab5b1ccbda/COVID-19%20-%20Clinical%20Presentation%20V2_Galaxy.pdf))
  
 ===== Interactions ===== ===== Interactions =====
Line 46: Line 86:
  
 === Adverse Events === === Adverse Events ===
 +
 +===== Mechanisms =====
 +{{ ::hcq_action_mechanism_w_covid.png?600 |}}
 +If hydroxychloroquine could help with Omicron, would politics block its use?
 +Dr Philip McMillan - Oct 31, 2022 ((https://philipmcmillan.substack.com/p/if-hydroxychloroquine-could-help))
 +
 +  * Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture((September 14, 2022 | Zixuan Yuan et al | Nature (journal) | Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture | [[https://www.nature.com/articles/s42003-022-03841-8|doi.org/10.1038/s42003-022-03841-8]]))
 +
  
  
Back to top